替罗非班对冠脉复杂病变介入治疗影响分析

目的 评价血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂替罗非班对冠脉复杂病变介入治疗心肌保护作用及安全性。方法 选取本科冠心病患者136例,随机分为两组：替罗非班组及对照组,其中替罗非班组70例,对照组66例,给予冠脉造影、PTCA、置入支架,其中替罗非班组术后给予替罗非班以8ml/h静脉滴注24~36h,并给予阿司匹林、波利维及低分子肝素治疗,检测患者术后及术后12h、24h心电图、心肌酶、血小板聚集率检查;对照组给予阿司匹林、波利维及低分子肝素治疗,术后进行同样检查,并观察所有患者的并发症：皮肤、牙龈及内脏出血。结果 两组相比年龄、病变类型及相关危险因素相似,两组心肌酶、心电图（ECG）ST段最大偏移、血小板聚集率比较有显著性差异,有1例出现消化道出血,无血小板减少发生。结论 替罗非班对复杂病变介入治疗具有心肌保护作用,可降低出血率并降低介入治疗后急性及亚急性血栓发生率。

Clinical investigation of Tirofiban in influence of percutaneous coronary intervention for complex coronary artery disease

Objective to evaluate the protectiveness and safety of platelet GP Ⅱb/Ⅲa receptor antagonist Tirofiban in complex coronary artery diseases patients undergoing percutaneous coronary intervention （ PCI）. Methods 136 cases of CHD patients in cardiology unit in Shandong Provincial hospital were selected and randomly divided into Tirofiban group （70 cases）and control group （66 cases）. For the control group, patients only received Asprin, Clpidogrel sulfat and low-molecular Heparin, In Tirofiban group, patients were received the same medicine as the control group together with Tirofiban 8 ml/h infusion for 24-36 h. ECG, cardiac muscle enzymes,platelet aggregation were monitored immediate after operation and 12hr post operation,and also the hemorrhage of skin,teeth and other organs were observed. Results There was singnificantly different in cardiac enzymes,maxSTE of the rate of platelet aggregation between the two groups. Conclusion Tirofiban is efficacy and safety in protecting heart in patients undergoing PCI, lower the incidence of hemorrhage,and also can reduce the occurrence of acute and subacute thrombosis.